BioMerieux exceeds financial expectations in 2016

BioMerieux has announced its financial results for the 2016 business year, during which it was able to outperform its own internal expectations.

The company's consolidated sales for the year came to 2.1 billion euros (1.78 billion pounds), representing a year-on-year increase of 7.1 percent on a reported basis, or a 9.6 percent rise in terms of organic sales growth.

All regions and all strategic lines contributed to this strong performance, with the Americas region making a particularly significant contribution, while the success of the FilmArray molecular biology brand was another highlight.

As such, the company expects its contributive operating income before non-recurring items to be slightly above its previous target, edging closer to the 300 million euro mark than anticipated.

Alexandre Merieux, chief executive officer at BioMerieux, said: "The company will continue to pursue its strategic investments in order to innovate and provide its customers with high value-added medical solutions, making a lasting contribution to improved patient care."

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.